MA54150A - Compositions et méthodes de traitement de troubles dépendant des oestrogènes - Google Patents

Compositions et méthodes de traitement de troubles dépendant des oestrogènes

Info

Publication number
MA54150A
MA54150A MA054150A MA54150A MA54150A MA 54150 A MA54150 A MA 54150A MA 054150 A MA054150 A MA 054150A MA 54150 A MA54150 A MA 54150A MA 54150 A MA54150 A MA 54150A
Authority
MA
Morocco
Prior art keywords
compositions
methods
estrogen dependent
dependent disorders
treating estrogen
Prior art date
Application number
MA054150A
Other languages
English (en)
Inventor
Jean-Pierre Gotteland
Ernest Loumaye
Oliver Pohl
Original Assignee
ObsEva SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ObsEva SA filed Critical ObsEva SA
Publication of MA54150A publication Critical patent/MA54150A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MA054150A 2018-11-07 2019-11-06 Compositions et méthodes de traitement de troubles dépendant des oestrogènes MA54150A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862756946P 2018-11-07 2018-11-07

Publications (1)

Publication Number Publication Date
MA54150A true MA54150A (fr) 2021-09-15

Family

ID=68618113

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054150A MA54150A (fr) 2018-11-07 2019-11-06 Compositions et méthodes de traitement de troubles dépendant des oestrogènes

Country Status (7)

Country Link
US (1) US20230067378A1 (fr)
EP (1) EP3876943A2 (fr)
JP (1) JP7459086B2 (fr)
KR (1) KR20210100623A (fr)
MA (1) MA54150A (fr)
SG (1) SG11202104053TA (fr)
WO (1) WO2020094698A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201911598WA (en) 2017-06-05 2020-01-30 ObsEva SA Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
SG11201911599XA (en) 2017-06-05 2020-01-30 ObsEva SA Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
CA3117092A1 (fr) 2018-10-29 2020-05-07 ObsEva S.A. Compositions et methodes de traitement de l'endometriose interne et de l'endometriose rectovaginale
AU2020325655B2 (en) * 2019-08-08 2025-09-11 Kissei Pharmaceutical Co., Ltd. Compositions and methods for the treatment of estrogen-dependent disorders
BR112022023937A2 (pt) * 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
CN115232144B (zh) * 2021-04-22 2024-04-02 长春金赛药业有限责任公司 含氮稠环类衍生物、药物组合物及其制备方法和应用
AU2023325806A1 (en) * 2022-08-16 2025-03-06 Cms Research & Development Pte. Ltd. Salt type and crystal form of thienopyrimidinone derivative
WO2026060502A1 (fr) * 2024-09-23 2026-03-26 Klautau Leite Ana Paula Système de diagnostic par image de l'endométriose profonde et/ou de l'adénomyose, et procédé d'analyse d'examens d'image

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960591B2 (en) 2000-07-05 2005-11-01 Yamanouchi Pharmaceutical Co., Ltd. Propane-1,3-dione derivative
EP1591446B1 (fr) 2003-01-29 2013-03-06 Takeda Pharmaceutical Company Limited Composés de thienopyrimidine et utilisation
AU2004257639B2 (en) 2003-07-07 2011-01-06 Neurocrine Biosciences, Inc. Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
PL1939204T6 (pl) 2005-10-19 2024-03-25 Kissei Pharmaceutical Co., Ltd. Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja oraz jej zastosowanie medyczne
JP5337261B2 (ja) 2010-02-10 2013-11-06 キッセイ薬品工業株式会社 縮合複素環誘導体の塩及びその結晶
WO2014042176A1 (fr) * 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 Procédé de production d'un dérivé hétérocyclique fusionné, et production intermédiaire
UA123114C2 (uk) 2016-08-08 2021-02-17 Кіссеі Фармасьютікал Ко., Лтд. СПОСІБ ЛІКУВАННЯ ЕНДОМЕТРІОЗУ 3-[2-ФТОР-5-(2,3-ДИФТОР-6-МЕТОКСИБЕНЗИЛОКСИ)-4-МЕТОКСИФЕНІЛ]-2,4-ДІОКСО-1,2,3,4-ТЕТРАГІДРОТІЄНО[3,4-d]ПІРИМІДИН-5-КАРБОНОВОЮ КИСЛОТОЮ
SG11201911599XA (en) * 2017-06-05 2020-01-30 ObsEva SA Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
AU2018419533A1 (en) * 2018-04-19 2020-11-12 Abbvie Inc. Methods of treating heavy menstrual bleeding

Also Published As

Publication number Publication date
JP7459086B2 (ja) 2024-04-01
JP2022506368A (ja) 2022-01-17
WO2020094698A2 (fr) 2020-05-14
SG11202104053TA (en) 2021-05-28
US20230067378A1 (en) 2023-03-02
EP3876943A2 (fr) 2021-09-15
KR20210100623A (ko) 2021-08-17
WO2020094698A3 (fr) 2020-08-06

Similar Documents

Publication Publication Date Title
MA54150A (fr) Compositions et méthodes de traitement de troubles dépendant des oestrogènes
EP3448398A4 (fr) Compositions et méthodes pour le traitement de troubles cutanés
EP3902536A4 (fr) Compositions et méthodes de traitement de troubles neurodégénératifs
EP3328376A4 (fr) Méthodes et compositions pour le traitement de troubles de la reprogrammation métabolique
EP3389725A4 (fr) Compositions et méthodes pour le traitement de maladies du système nerveux central
EP3500267A4 (fr) Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs
EP3423100A4 (fr) Compositions destinées à traiter l'inflammation et méthodes de traitement associées
EP3368088C0 (fr) Compositions et méthodes pour le traitement de troubles du peroxisome et de leucodystrophies
EP3727403A4 (fr) Méthodes intracanalaires de traitement de troubles du sein
EP3661553A4 (fr) Méthodes et compositions pour le traitement des maladies à dépôts amyloïdes
EP3518923A4 (fr) Méthodes de traitement de troubles mitochondriaux et métaboliques
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
EP3359258A4 (fr) Compositions et méthodes de traitement de troubles fibreux de la peau
EP3692023A4 (fr) Composés benzothiazol et méthodes d'utilisation de ceux-ci pour traiter des troubles neurodégénératifs
EP3600285A4 (fr) Compositions topiques et méthodes de traitement
EP3352749A4 (fr) Composés et compositions pour le traitement de troubles oculaires
EP3801768A4 (fr) Méthodes de traitement de troubles du hyperprolifératifs malins
EP3313417A4 (fr) Méthodes de traitement de troubles auto-immuns et allo-immuns
EP3826650A4 (fr) Méthodes de traitement de troubles neurologiques
EP3979996A4 (fr) Méthodes et compositions de traitement de troubles de la vue
EP3334710A4 (fr) Compositions et méthodes de traitement et de prévention de troubles neurodégénératifs
EP3442554A4 (fr) Compositions et méthodes pour le traitement de troubles associés à la néovascularisation
EP3952851A4 (fr) Composés et méthodes de traitement de troubles inflammatoires
EP3364965A4 (fr) Méthodes et compositions pour le traitement de maladies neurodégénératives
EP3518951A4 (fr) Compositions et méthodes pour le traitement d'affections orthopédiques